Technological Advancements to Result in Hospital-Acquired Infection (HAI) Diagnostics Domain Growth

AGOURA HILLS, Calif. - Oct. 29, 2019 - PRLog -- It generated a $2,657.6 million revenue in 2016, and is expected to grow at a 7.6% CAGR during the forecast period (2017–2023). HAIs, also known as nosocomial infections, are caught on during hospitalization at nursing homes, hospitals, outpatient clinics, rehabilitation centers, and other clinical settings.

The development of technologically advanced products is one of the key driving factors for the HAI diagnostics market. Advancements in technology have resulted in the development of products that offer low turnaround time and reliable results. This has resulted in the development of molecular diagnostics as a separate niche, which is attracting many companies to invest in it. For instance, the cobas Liat PCR system with four assays was launched by Roche Diagnostics in 2017, which can conduct a 20-minute real-time PCR nucleic acid test for Clostridium difficile detection.

Request to Get the Sample Pages at:

https://www.psmarketresearch.com/market-analysis/hospital-acquired-infection-diagnostics-market/report-sample

The application segment of the HAI diagnostics market (https://www.psmarketresearch.com/market-analysis/hospital...) is subdivided into drug resistance testing and disease testing. The diagnosis process has become easier and more accurate with the inclusion of advanced technology that has led to the development of many modern techniques. Technological advancements have resulted in the development of mass spectrometry, nucleic acid-based technology, isothermal microcalorimetry, flow cytometry, and near-infrared spectroscopy, which are heavily employed in the diagnosis of infectious diseases. This is expected to result in the faster growth of the disease testing category at a 7.9% CAGR during the forecast period.

The categories of the test type segment of the HAI diagnostics market are urinalysis, molecular diagnostics, and immunoassay. During the forecast period, the molecular diagnostics category is expected to grow the fastest, at a 12.9% CAGR. This is attributed to the increasing awareness and acceptance of personalized medicine, rising infectious disease prevalence, and growing research on biomarker identification techniques. Emerging economies are also adopting molecular diagnostics, thereby presenting the market an amazing opportunity for growth.

Therefore, the market is set to advance in the forecast period due to technological advancements, growing geriatric population, and rising prevalence of HAIs in emerging economies as well.